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Plasma cell-free DNA 
methylation: a liquid biomarker 
of hepatic fibrosis
We recently reported dynamic epigenetic 
markers of fibrosis detectable in patients’ 
plasma that may have utility in non-inva-
sive diagnosis and staging of fibrosis in 
patients with chronic liver disease.1 Specif-
ically, we uncovered DNA methylation 
markers at the human PPARγ promoter 
detectable in circulating cell-free DNA 
(ccfDNA) that display differential methyl-
ation densities. Remarkably, PPARγ hyper-
methylation correlated with progression 
to cirrhosis in alcoholic liver disease (ALD) 
and with specific stages of liver fibrosis in 
non-alcoholic fatty liver disease (NAFLD). 
Furthermore, ccfDNA signatures were 
traced back to the molecular pathology in 
fibrotic liver tissue, providing a biomarker 
of the underlying pathological process 
and defining hepatocytes as the source of 
hypermethylated DNA found in plasma.1 
The original study posed several 
important outstanding questions: (1) 
Can ccfDNA methylation be used as a 
biomarker of fibrosis in liver diseases of 
other aetiologies? (2) Does the presence 
of hepatocellular carcinoma (HCC) alter 
the biomarker in plasma? (3) Does pres-
ence of fibrosis in other organs generate 
similar biomarker profiles?
In the present letter, we answer these 
questions and demonstrate the broader 
utility of DNA methylation at three CpG 
dinucleotides within PPARγ promoter in 
several new patient cohorts (figure 1A 
and table 1). Employing pyrosequencing 
we detect hypermethylation at all three 
CpGs in ccfDNA from a cohort of patients 
suffering from cirrhosis caused by chronic 
HBV infection (figure 1B–D). The level of 
hypermethylation resembled that found in 
patients with cirrhotic NAFLD and ALD 
in our original study. However, since the 
HBV cohort was of another ethnicity to our 
original UK-based patients with NAFLD 
and ALD, we also measured methylation 
density in a Turkish NAFLD cohort, which 
was mirroring those detected in the HBV 
cohort. Our new data also demonstrate 
that presence of HCC with chronic liver 
disease does not alter the specificity of 
the DNA methylation markers for detec-
tion of liver fibrosis (figure 1B–D). As we 
had access to explant liver tissue from 
patients with NAFLD, HBV and HCC, 
we determined methylation densities in 
the liver (figure 1E–G). A high similarity 
was observed between the degree of DNA 
methylation at PPARγ gene promoter in 
ccfDNA and in the patient-matched liver 
tissues. We found a significant spread of 
values for DNA methylation in the healthy 
control ccfDNA, this being in contrast 
with our original UK-based study in which 
low-level methylation density was consis-
tent across individuals within the control 
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Figure 1 (A) Schematic representation of human PPARγ gene promoter showing the positions 
of the differentially methylated CpGs 1, 2 and 3. (B–D) Plasma cell-free DNA methylation 
as determined by pyrosequencing at (B) CpG1, (C) CpG2 and (D) CpG3 within the human 
PPARγ gene promoter from control donors or patients with NAFLD, HBV, HCC or SSc. n, shows 
the number of individual patients within each cohort. DNA methylation was quantitatively 
measured and expressed as a percentage. Error bars represent mean values±95% CI;  *P<0.05, 
**P<0.01, ***P<0.001. (E–G) Whole liver DNA methylation at (E) CpG1, (F) CpG2 and (G) CpG3 
within the human PPARγ gene promoter in patients with NAFLD, HBV and HCC. All methods are 
listed in the online supplementary file. cfDNA, cell-free DNA; HCC, hepatocellular carcinoma; 
NAFLD, non-alcoholic fatty liver disease; SSc, systemic sclerosis.
 Gut Online First, published on January 20, 2018 as 10.1136/gutjnl-2017-315668
Copyright Article author (or their employer) 2018. Produced by BMJ Publishing Group Ltd (& BSG) under licence. 
group.bmj.com on January 26, 2018 - Published by http://gut.bmj.com/Downloaded from 
2 Gut Month 2018 Vol 0 No 0
PostScript
group. We are unable to explain this wider 
spread of methylation densities in the 
Turkish cohort, but cannot rule out an 
undetected liver disease in the apparently 
‘healthy’ controls that display elevated 
ccfDNA methylation.
We next determined if hypermethyla-
tion is specific to fibrosis of liver origin. 
To this end, we quantified ccfDNA 
methylation in a cohort of patients with 
limited and diffuse systemic sclerosis 
(SSc) who have various combinations of 
skin, lung and kidney fibrosis, but no 
hepatic fibrosis.2 All three CpG sites 
in SSc were relatively hypomethylated 
(figure 1B–D), with similar methylation 
densities between individual patients 
with SSc. All methods relating to the 
study are listed in ‘online supplemen-
tary materials and methods 1’.
This important validation study supports 
our original hypothesis that hypermeth-
ylation at the PPARγ gene promoter is a 
marker for fibrotic progression of chronic 
liver disease and holds true for viral, alco-
holic and metabolic disease aetiologies. As 
fibrosis in other organs does not generate 
a similar epigenetic signature, it is likely 
that the PPARγ hypermethylation specifi-
cally reflects a liver pathology. The ability 
to detect and quantify hypermethylation 
at the promoter of the PPARγ in ccfDNA 
as a new liquid biomarker that specifically 
reports the fibrotic progression of liver 
diseases of multiple aetiologies offers the 
potential for a cost-effective blood-based 
liquid biomarker of liver fibrosis.
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Table 1 Characteristics of patient cohorts used in the study
Age (years) Gender (male/female) BMI (kg/m2) Diabetes (%) ALT (IU/L) AST (IU/L)
NAFLD cohort 56 ± 7 10/3 29.8±3.2 69 33±23 54±36
Hepatitis B cohort 51±7 10/3 26.5±2.4 38 47±50 80±64
HCC cohort 57±7 16/1 27.5±4.2 29 55±36 65±53
Systemic 
sclerosis 
cohort
(n=30)
Age 
(years)
Gender
(male/female)
BMI
(kg/m2)
Diffuse 
cutaneous 
limited 
SSc
Disease 
duration 
(years)
Heart 
involvement
Lung 
involvement 
DLCO 
(%)
Antinuclear 
antibody-
positive
Anticentromere 
antibody-
positive
Antitopoisomerase I 
antibody-positive
55±14 10/20 26±3.8 12 (40%) 7.5±4 2 (7%) 11 (37%) 71.7±17 30 (100%) 11 (37%) 12 (40%)
Notes: Viral hepatitis in HCC cohort: HBV-positive, n=8; HCV-negative, n=2; HBV-positive and HCV-positive, n=3. 
Data expressed as mean±SD or median (range). 
BMI, body mass index; HCC, hepatocellular carcinoma; NAFLD, non-alcoholic fatty liver disease; SSc, systemic sclerosis.   
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Supplementary materials and methods to the letter “Plasma cell free DNA 
methylation: a liquid biomarker of hepatic fibrosis” 
 
Clinical Cohorts 
Use of human tissue was approved by Koç University Ethics Committee for Clinical 
Research (04.02.2016 - 2016.024.IRB2.005). Informed consent was obtained from all 
participants. All liver samples were collected and used subject to patient’s written 
consent prior to the day of liver transplantation. Blood samples and liver tissues were 
collected during transplantation. Clinical and laboratory data were collected at the 
time of surgery.  
NAFLD cohort- The NAFLD diagnosis was based on imaging findings and 
histologic examination of the explanted liver. Patients with alternative diagnosis 
(chronic viral hepatitis, viral autoimmune liver disease, drug-induced liver injury, 
haemochromatosis, Wilson’s disease, alpha-1-antitrypsin deficiency) were excluded. 
Patients who consumed more than 20 g of alcohol per day for males or more than 10 g 
per day for females were excluded.  
HBV and HCC cohort- For the HBV cohort, patients were selected based on the 
medical records with a positivity for hepatitis B surface antigen; patients with 
alternate liver diagnoses or evidence of coexistent liver disease were excluded. 
Diagnosis of HCC was made if typical features were detected on computed 
tomography/magnetic resonance and by pathologic examination. Severity of fibrosis 
was assessed on explanted liver tissues. 
Clinical details such as gender, age, weight, height were obtained from all patients at 
the time of transplantation. The body mass index (BMI) was calculated by the 
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formula: weight (kg)/height2 (m2). Patients were identified as having type 2 diabetes if 
they were receiving dietary, oral hypoglycaemic drug or insulin treatment, or had 
fasting blood glucose >7.0 mmol/L. For the control cohort, use of human tissue was 
approved by Koç University Ethics Committee for Clinical Research (18.9.2015- 
2015.215.IRB1.020). Subjects had no signs or symptoms of liver disease, and no 
history of chronic illnesses. 
Scleroderma Cohort - Systemic sclerosis (SSc) patients were recruited from a study 
site managed by Professor Jörg Distler, Professor for translational matrix biology, 
University of Erlangen-Nuremberg. Blood samples from patients were collected 
subject to patients’ written consent. Recruited patients fulfilled the American College 
of Rheumatology (ACR)/ European League against Rheumatology (EULAR) criteria 
for the diagnosis of systemic sclerosis. SSc was classified according to the 
conventional criteria defined by LeRoy et al [1]. “Diffuse SSc” was diagnosed if the 
skin thickening extends proximal to the elbows and knees or includes the trunk, while 
“Limited SSc” was diagnosed if the skin thickening was confined to the elbows and 
knees, or to the face. Thirty SSc patients were recruited in total; eighteen had limited 
cutaneous SSc and twelve had diffuse cutaneous SSc.  Information collected at time 
of blood sample collection involved clinical details (gender, age, weight, height, 
disease duration, organ involvement) and laboratory data (including Scleroderma 
related antibodies). The body mass index (BMI) was calculated by the formula: 
weight (kg)/height2 (m2). Lung involvement was considered present if there was 
evidence of pulmonary fibrosis or pulmonary arterial hypertension. Heart 
involvement was defined by a past/current diagnosis of congestive heart failure, 
cardiac arrhythmia, pericarditis, a pericardial effusion, or cardiomegaly.  
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Cell free circulating and liver DNA extraction 
Whole blood was collected into EDTA and the plasma was separated by 
centrifugation for 10 min at 3000rpm followed by transfer to new tubes and re-
centrifugation. For the chronic liver disease and hepatocellular carcinoma cohort, 
liver tissues were selected 3 cm away from tumour margin.  Genomic DNA was 
extracted from plasma and liver specimens using QIAamp DNA Blood Mini or Micro 
Kit (Qiagen, Germany, catalogue no: 51106 - 56304). Plasma and liver tissues were 
lysed at 56°C for 10 minutes and overnight respectively. The lysate was processed 
and transferred to spin columns as per manufacturer’s instructions.   
Bisulfite modification  
EZ DNA Methylation Gold TM Kit (Zymo Research, Irvine, CA, USA) was used for 
bisulfite conversion of genomic DNA. Cell free circulating and liver tissue DNA were 
bisulfite modified by incubating at 98°C for 10 min and 64°C for 2 h and 30 min. 
Product was transferred into columns; desulphonated and washed according to 
manufacturer’s protocol and eluted in elution buffer. A 5µl of bisulphite modified cell 
free DNA was amplified in a PCR mix containing 2µl of forward and reverse primer, 
12.5µl of HotStarTaq Master Mix Kit (Qiagen, Germany, catalogue no: 203445) or 
Pyromark PCR kit (Qiagen, Germany, catalogue no: 978703) and 5.5µl of water. 
2.5µl Q solution and 1.5µl MgCl2 (25mM/ml) were added. Amplification of DNA 
was performed in a thermocycler according to the following PCR conditions: one 
cycle at 95°C for 6 min, followed by 50 cycles of 95°C for 30 s, annealing 
temperature of 55°C for 30 s and 72°C for 30 s, followed by one cycle at 72°C for 30 
s.  
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Pyrosequencing analysis 
Methylation of specific cytosines within CpG dinucleotides was quantified by 
pyrosequencing using a Pyromark Q96 ID (Qiagen) instrument. PCR and sequencing 
primers were obtained from a custom designed assay for PPARγ as previously 
described [2]. 10µl of biotin-labelled PCR product was used in each well and 
combined by streptavidin- coated sepharose beads, washed in 70% ethanol, denatured 
in denaturation buffer (Qiagen, PyroMark Denaturation Buffer, 979007) and washed 
in a wash buffer (Qiagen, PyroMark Wash Buffer, 979008). Sequencing primers were 
annealed to DNA product at 80°C. The samples were analyzed in duplicate, and the 
mean of the two measurements was used as the final value. Assay efficiency was 
validated by fully unmethylated as well as fully methylated DNA (Qiagen, EpiTect 
PCR Control DNA Set, 59695). CpG methylation data was analysed by Pyro Q-CpG 
software 1.0.6.  
Statistical analysis 
All statistical analyses and graphs were made using GraphPad Prism Software. 
Continuous normally distributed variables were represented as mean ± standard 
deviation (SD). To determine differences between groups for continuous non-
normally distributed variables, means were compared using the Mann-Whitney U test.  
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